Pathos AI completed the acquisition of a 77% stake in Rain Oncology.

Pathos AI, a clinical stage biotechnology company, completed the acquisition of a 77% stake in Rain Oncology, a precision oncology company. Financial terms were not disclosed. “After a thorough assessment, the Rain Board determined that this Transaction is in the best interests ofour stockholders, as it leverages Rain’s strong cash position to provide a confirmed cash takeout for our stockholders and retains some future potential upside due to Pathos’ continued interest in further developing milademetan for cancer patients using their proprietary PathOS Platform,” Avanish Vellanki, Rain Co-Founder and CEO.